IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
116.29
+0.02 (+0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close116.27
Open116.02
Bid114.00 x 800
Ask117.18 x 1000
Day's Range115.40 - 116.61
52 Week Range100.22 - 120.06
Volume1,486,280
Avg. Volume2,363,809
Net Assets9.57B
NAV116.50
PE Ratio (TTM)4.04
Yield0.28%
YTD Return9.26%
Beta (3y)1.50
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • MarketWatch10 days ago

    Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems'

    Shares of Gemphire Therapeutics Inc. (gemp) plunged 17% toward a record low Friday after the biopharmaceutical company said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems." The company said the data and safety monitoring board at Emory University overseeing the trial recommended the termination. Gemphire said data on the first three patients undergoing 12 weeks of treatment all experienced an increase in liver fat content, which was deemed an unexpected problem.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist10 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • How Ionis’s Q2 2018 Earnings Trended
    Market Realist12 days ago

    How Ionis’s Q2 2018 Earnings Trended

    Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.

  • MarketWatch12 days ago

    Ampio's stock plunges below $1 threshold after FDA comments on clinical trial

    Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.

  • Investopedia12 days ago

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.

  • Estimates and Recommendations for BeiGene on August 7
    Market Realist12 days ago

    Estimates and Recommendations for BeiGene on August 7

    BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.

  • Investopedia17 days ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • ETF Trends19 days ago

    Biotech ETFs Rally as Illumina Tops Q2 Expectations

    Biotechnology sector ETFs were among the best performers Tuesday, with Illumina (ILMN) shares surging after the genomics firm beat second-quarter expectations and raised its year-end outlook. Among the best performing ETFs of Tuesday, the Invesco Dynamic Biotech & Genome (PBE) increased 3.0%, ARK Genomic Revolution Multi-Sector ETF (ARKG) advanced 2.5% and iShares Nasdaq Biotechnology ETF (IBB) rose 2.0%. Evercore analyst Ross Muken said in that the Illumina stock story is "far too compelling to ignore," reports Allison Gatlin for Investor's Business Daily.

  • What to Expect from Shire’s Q2 2018 Earnings on July 31
    Market Realist20 days ago

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

  • Amgen Beats Estimates, Reports Growth in Q2 2018
    Market Realist24 days ago

    Amgen Beats Estimates, Reports Growth in Q2 2018

    Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates. It reported non-GAAP EPS of $3.83 on revenue of ~$6.1 billion, while analysts had expected EPS of $3.54 on revenue of $5.7 billion. The chart below shows Amgen’s EPS and revenue since Q1 2017.

  • Celgene Raises Revenue Guidance after Solid Growth in Q2 2018
    Market Realist24 days ago

    Celgene Raises Revenue Guidance after Solid Growth in Q2 2018

    In the second quarter of 2018, Celgene (CELG) reported revenues of $3.8 billion, compared to $3.3 billion in the second quarter of 2017, reflecting ~17% growth on a year-over-year (or YoY) basis and ~8% growth sequentially.

  • MarketWatch26 days ago

    ResTORbio's stocks rockets on positive trial results, just as post-IPO lock up expires

    Shares of resTORbio Inc. (torc) nearly tripled in premarket trade Wednesday, after the biopharmaceutical company announced positive results from its dose-ranging phase 2b trial of its treatment for respiratory tract infections (RTIs). The company said RTB101 demonstrated a statistically significant and clinically meaningful reduction in the percentage of patients with one or more RTIs during the treatment period, the primary endpoint of the study with the 10 mg once-daily dose, while RTB101 10 mg in combination with everolimus 0.1 mg didn't meet the primary endpoint.

  • MarketWatch27 days ago

    Biotech ETFs surge, supported by strong results from Biogen and Eli Lilly

    MARKET PULSE Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected quarterly results from a pair of major components. The iShares Nasdaq Biotechnology ETF (IBB) gained 1.

  • Why Amgen’s Revenue Is Expected to Fall in Q2 2018
    Market Realist27 days ago

    Why Amgen’s Revenue Is Expected to Fall in Q2 2018

    As discussed previously, analysts expect Amgen’s (AMGN) revenue to fall 1.3% YoY (year-over-year) to $5.7 billion in Q2 2018. The graph below shows Amgen’s revenue since Q1 2017, and Q2 2018 estimates. While new product sales are expected to see double-digit growth, legacy product sales are expected to fall.

  • Trending: Disillusioned Investors Punish Netflix Stock Due to Subscriber Shortfall
    ETF Databaselast month

    Trending: Disillusioned Investors Punish Netflix Stock Due to Subscriber Shortfall

    Netflix failed to meet market expectations, posting disappointing subscriber adds and lowering third-quarter targets.

  • InvestorPlacelast month

    Trump Tweets Threat to Pfizer but Investors Shrug it Off

    Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.

  • ETF Trendslast month

    Biotech ETFs Climb on Biogen’s Promising Clinical Trial

    Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...

  • InvestorPlacelast month

    Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough

    Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.

  • MarketWatchlast month

    Biotech ETFs surge, lifted as Biogen sees best session in more than a decade

    MARKET PULSE Exchange-traded funds that track the biotechnology sector jumped on Friday, supported by a huge gain in industry bellwether Biogen, which climbed after a positive drug trial. The iShares Nasdaq Biotechnology ETF (IBB) jumped 2.

  • TheStreet.comlast month

    Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

    First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.

  • Go Long Pfizer Stock — It’s an Easy Pill to Swallow
    InvestorPlacelast month

    Go Long Pfizer Stock — It’s an Easy Pill to Swallow

    Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.

  • It May Be Imperfect, but Celgene’s Growth Is Worth Taking Note of
    InvestorPlace2 months ago

    It May Be Imperfect, but Celgene’s Growth Is Worth Taking Note of

    Are shares of Celgene Corporation (NASDAQ:CELG) finally bottoming? Without news flow for the stock to react on, it’s hard to confirm whether the peak-to-trough drop of 49.6% in CELG stock is over or if more losses are still to come. Celgene is far from perfect.

  • EARNINGS: United Health slumps after guidance disappoints Wall Street
    Yahoo Finance Videolast month

    EARNINGS: United Health slumps after guidance disappoints Wall Street

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after United Health Group reports second quarter net income that beat Wall Street expectations. Here's the performance of select health care stocks as of 10:00 am ET: JNJ Johnson & Johnson 3.67% NKTR(0) Nektar Therapeutics 1.36% ABT Abbott Laboratories 1.07% HCA HCA Hldg Inc 0.88% LLY Lilly (Eli) 0.79% ALXN Alexion Pharmaceuticals 0.80% CELG Celgene Corp 0.72% COO Cooper Cos 0.54% BIIB Biogen Inc 0.54% PFE Pfizer Inc 0.49% BSX Boston Scientific Corporation 0.54% MDT Medtronic plc 0.42% SYK Stryker Corp 0.51% PRGO(HB) Perrigo Co plc 0.35% IBB iShs Nasdaq BioTech ETF 0.37% BMY Bristol-Myers SQUIBB 0.35% EVHC Envision Healthcare Corp 0.34% VAR Varian Medical Systems Inc 0.28% UHS Univl Health Svs'B' 0.24% MRK Merck & Co 0.16% ZTS Zoetis Inc 0.22% BAX Baxter Intl Inc 0.18% INCY Incyte Corp 0.10% BDX Becton, Dickinson 0.15% REGN Regeneron Pharmaceuticals 0.08% IDXX Idexx Laboratories 0.16% VRTX Vertex Pharmaceuticals 0.11% ABMD Abiomed, Inc 0.03% SHPG Shire plc ADS 0.12% BMRN Biomarin Pharmaceutical 0.10% XRAY Dentsply Sirona Inc 0.09% GILD Gilead Sciences 0.03% XLV S&P Sel Health Care Spdr Fd 0.02% ISRG Intuitive Surgical -0.03% ABC AmeriSourceBergen Corp -0.10% IQV IQVIA Hldgs Inc 0.01% ZBH Zimmer Biomet Hldgs Inc -0.04% HOLX Hologic Inc 0.00% DGX Quest Diagnostics -0.14% ALGN Align Tech 0.11% AGN Allergan plc -0.31% TMO Thermo Fisher Scientific Inc -0.17% HSIC Henry Schein Inc -0.24% EW Edwards Lifesciences Corp -0.19% RMD Resmed Inc -0.21% AET Aetna Inc -0.40% MCK McKesson Corp -0.54% ABBV AbbVie Inc -0.34% DVA DaVita Inc -0.48% MYL Mylan NV -0.49% CAH Cardinal Health Inc -0.71% AMGN Amgen Inc -0.68% LH Laboratory Corp Amer Hldgs -0.68% CNC Centene Corp -1.75%

  • Drug pricing debate could heat up in July
    CNBC Videoslast month

    Drug pricing debate could heat up in July

    CNBC's Meg Tirrell reports on drug prices and hikes that have already occurred this month. With Michael Yee, Jefferies.